Which biotech stocks should investors take a hard look at buying now? Health care analyst Max Macaluso sat down with Fool.com contributor Keith Speights recently to find out which stocks he likes in the biotech sector. Two big biotechs that Keith recommends are Biogen Idec (BIIB 4.56%) and Celgene (CELG).
Biogen and Celgene are both established companies with solid revenue. Biogen's multiple sclerosis drugs position it as a leader in that market. Likewise, Celgene's Revlimid stands at the top in treating multiple myeloma and myelodysplastic syndromes. Biogen and Celgene also count promising new drugs that have the potential to drive revenue even higher.
Both of these biotechs are red hot these days. Biogen shares are up over 33% so far in 2013. Celgene is up even more, rising 50% year-to-date. In this video interview, Max talks with Keith about why these hot biotech stocks should continue to do well over the long run.
